Skip to main content
SpringerLink
Log in

New Antifungal Agents and New Formulations Against Dermatophytes

  • Chapter
  • First Online:
Dermatophytes and Dermatophytoses

  • 850 Accesses

Abstract

There are a plethora of antifungal agents available for the treatment of onychomycosis. Systemic antifungal drugs are generally recommended for severe onychomycosis, while topical antifungal agents and devices are recommended for mild to moderate onychomycosis. Oral terbinafine is the gold standard treatment of onychomycosis, with high cure rates and proven treatment success. Novel therapies and newer antifungal formulations are under development. New topical formulations focus on enhanced drug penetration into the nail plate through multiroute administration to eliminate the infection from the nail bed. Effective management of onychomycosis is vital to combat increasing treatment failures, antifungal resistance and incidences of non-dermatophyte mold onychomycosis and mixed infections. Patients should be educated about nail hygiene, proper sanitization of shoes and socks, wearing proper footwear in communal showers and public pools, keeping feet dry, and prophylaxis post-treatment. Important steps in maximizing treatment success are combination therapy and inclusion of agents targeting fungal biofilms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st century: an update on diagnosis, epidemiology, and treatment. J Cutan Med Surg. 2017;21(6):525–39.

    Article  PubMed  Google Scholar 

  2. Wolverton SE, Wu JJ. Comprehensive dermatologic drug therapy e-book. Amsterdam: Elsevier Health Sciences; 2019. 186p.

    Google Scholar 

  3. Gupta AK, Uro M, Cooper EA. Onychomycosis therapy: past, present, future. J Drugs Dermatol. 2010;9(9):1109–13.

    PubMed  Google Scholar 

  4. Baran R, editor. Baran & Dawber’s diseases of the nails and their management. 5th ed. Hoboken, NJ: Wiley-Blackwell; 2019.

    Google Scholar 

  5. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol. 1994;30(5 Pt 1):677–98; quiz 698–700.

    Article  CAS  PubMed  Google Scholar 

  6. Ketoconazole. In: LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK547869/. Cited 27 Jan 2020.

  7. Anton Stutz inventions, patents and patent applications – Justia patents search [Internet]. https://patents.justia.com/inventor/anton-stutz. Cited 18 Feb 2020.

  8. Novartis Pharmaceuticals Corporation. Product monograph Lamisil (terbinafine hydrochloride) [Internet]. 2011. http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=13990. Cited 21 Aug 2012.

  9. Novartis. LAMISIL (terbinafine hydrochloride) Tablets, 250 mg [Internet]. Drugs@FDA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf. Cited 15 Mar 2013.

  10. Terbinafine Granules Approved by FDA for Tinea Capitis [Internet]. https://www.jwatch.org/pa200711210000001/2007/11/21/terbinafine-granules-approved-fda-tinea-capitis. Cited 14 Feb 2020.

  11. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126(Suppl 39):2–7.

    Article  PubMed  Google Scholar 

  12. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol. 1994;30(6):911–33; quiz 934–6.

    Article  CAS  PubMed  Google Scholar 

  13. Schatz F, Bräutigam M, Dobrowolski E, Effendy I, Haberl H, Mensing H, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol. 1995;20(5):377–83.

    Article  CAS  PubMed  Google Scholar 

  14. Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet. 2001;40(6):441–72.

    Article  CAS  PubMed  Google Scholar 

  15. Doty RL, Bromley SM. Effects of drugs on olfaction and taste. Otolaryngol Clin North Am. 2004;37(6):1229–54.

    Article  PubMed  Google Scholar 

  16. Terbinafine. In: LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548617/. Cited 16 Jan 2020.

  17. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf. 2000;22(1):33–52.

    Article  CAS  PubMed  Google Scholar 

  18. Wang Y, Lipner SR. Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration. J Dermatolog Treat. 2020:1–5.

    Google Scholar 

  19. Gupta AK, Ryder JE, Skinner AR. Treatment of onychomycosis: pros and cons of antifungal agents. J Cutan Med Surg. 2004;8(1):25–30.

    Article  PubMed  Google Scholar 

  20. Darkes MJM, Scott LJ, Goa KL. Terbinafine. Am J Clin Dermatol. 2003;4(1):39–65.

    Article  PubMed  Google Scholar 

  21. Cohen AD, Medvesovsky E, Shalev R, Biton A, Chetov T, Naimer S, et al. An independent comparison of terbinafine and itraconazole in the treatment of toenail onychomycosis. J Dermatolog Treat. 2003;14(4):237–42.

    Article  CAS  PubMed  Google Scholar 

  22. Gupta AK, Adamiak A, Cooper EA. The efficacy and safety of terbinafine in children. J Eur Acad Dermatol Venereol. 2003;17(6):627–40.

    Article  CAS  PubMed  Google Scholar 

  23. Janssen Pharma. SPORANOX® (itraconazole) capsules [Internet]. Drugs@FDA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020083s048s049s050lbl.pdf.

  24. Hector R. The many lives of itraconazole. Expert Opin Ther Pat. 2003;13(2):141–8.

    Article  CAS  Google Scholar 

  25. Korting HC, Schöllmann C. The significance of itraconazole for treatment of fungal infections of skin, nails and mucous membranes. J Dtsch Dermatol Ges. 2009;7(1):11–9.

    PubMed  Google Scholar 

  26. Gupta AK, Drummond-Main C, Cooper EA, Brintnell W, Piraccini BM, Tosti A. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66(3):494–502.

    Article  PubMed  Google Scholar 

  27. De Doncker P, Decroix J, Piérard GE, Roelant D, Woestenborghs R, Jacqmin P, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol. 1996;132(1):34–41.

    Article  CAS  PubMed  Google Scholar 

  28. Willemsen M, De Doncker P, Willems J, Woestenborghs R, Van de Velde V, Heykants J, et al. Posttreatment itraconazole levels in the nail: New implications for treatment in onychomycosis. J Am Acad Dermatol. 1992;26(5, Part 1):731–5.

    Article  CAS  PubMed  Google Scholar 

  29. De Doncker P. Pharmacokinetics of orally administered antifungals in onychomycosis. Int J Dermatol. 1999;38(Suppl 2):20–7.

    Article  PubMed  Google Scholar 

  30. Sigurgeirsson B, Billstein S, Rantanen T, Ruzicka T, di Fonzo E, Vermeer BJ, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. Br J Dermatol. 1999;141(Suppl 56):5–14.

    Article  PubMed  Google Scholar 

  31. Itraconazole. In: LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548273/. Cited Jan 16 2020.

  32. Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005;1(4):299–306.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Lavrijsen AP, Balmus KJ, Nugteren-Huying WM, Roldaan AC, van’t Wout JW, Stricker BH. Hepatic injury associated with itraconazole. Lancet. 1992;340(8813):251–2.

    Article  CAS  PubMed  Google Scholar 

  34. Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol. 1989;36(4):423–6.

    Article  PubMed  Google Scholar 

  35. Gupta AK, Stec N, Bamimore MA, Foley KA, Shear NH, Piguet V. The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol. 2020;34(3):580–8.

    Article  CAS  PubMed  Google Scholar 

  36. Havu V, Brandt H, Heikkilä H, Hollmen A, Oksman R, Rantanen T, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol. 1997;136(2):230–4.

    CAS  PubMed  Google Scholar 

  37. Huang P-H, Paller AS. Itraconazole pulse therapy for dermatophyte onychomycosis in children. Arch Pediatr Adolesc Med. 2000;154(6):614–8.

    Article  CAS  PubMed  Google Scholar 

  38. Gupta AK, Nolting S, de Prost Y, Delescluse J, Degreef H, Theissen U, et al. The use of itraconazole to treat cutaneous fungal infections in children. Dermatology (Basel). 1999;199(3):248–52.

    Article  CAS  Google Scholar 

  39. Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol. 2006;20(10):1188–93.

    Article  CAS  PubMed  Google Scholar 

  40. Fluconazole – an overview | ScienceDirect Topics [Internet]. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/fluconazole. Cited 18 Feb 2020.

  41. Pfizer. DIFLUCAN® (Fluconazole tablets) (Fluconazole for oral suspension) [Internet]. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019949s060,020090s044lbl.pdf.

  42. Scher RK, Breneman D, Rich P, Savin RC, Feingold DS, Konnikov N, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38(6 Pt 2):S77–86.

    Article  CAS  PubMed  Google Scholar 

  43. Bueno JG, Martinez C, Zapata B, Sanclemente G, Gallego M, Mesa AC. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Clin Exp Dermatol. 2010;35(6):658–63.

    Article  CAS  PubMed  Google Scholar 

  44. Gupta AK, Drummond-Main C, Paquet M. Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment. J Dermatolog Treat. 2013;24(1):75–80.

    Article  CAS  PubMed  Google Scholar 

  45. Brown SJ. Efficacy of fluconazole for the treatment of onychomycosis. Ann Pharmacother. 2009;43(10):1684–91.

    Article  CAS  PubMed  Google Scholar 

  46. Gupta AK, Daigle D, Foley KA. Network meta-analysis of onychomycosis treatments. Skin Appendage Disord. 2015;1:74–81.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166(5–6):353–67.

    Article  PubMed  Google Scholar 

  48. Fluconazole. In: LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548300/. Cited 16 Jan 2020.

  49. Spernovasilis N, Kofteridis DP. Pre-existing liver disease and toxicity of antifungals. J Fungi (Basel). 2018;4(4):133.

    Article  CAS  Google Scholar 

  50. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12(Suppl 3):S318–26.

    Article  PubMed  Google Scholar 

  51. Muńoz P, Moreno S, Berenguer J, Bernaldo de Quirós JC, Bouza E. Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1991;151(5):1020–1.

    Article  PubMed  Google Scholar 

  52. Stevens DA. The new generation of antifungal drugs. Eur J Clin Microbiol Infect Dis. 1988;7(6):732–5.

    Article  CAS  PubMed  Google Scholar 

  53. Sethi A, Antaya R. Systemic antifungal therapy for cutaneous infections in children. Pediatr Infect Dis J. 2006;25(7):643–4.

    Article  PubMed  Google Scholar 

  54. Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol. 2013;27(3):267–72.

    Article  CAS  PubMed  Google Scholar 

  55. Sprenger AB, Purim KSM, Sprenger F, Queiroz-Telles F. A week of oral terbinafine pulse regimen every three months to treat all dermatophyte onychomycosis. J Fungi (Basel). 2019;5(3):82.

    Article  CAS  Google Scholar 

  56. Gupta AK, Baran R, Summerbell R. Onychomycosis: strategies to improve efficacy and reduce recurrence. J Eur Acad Dermatol Venereol. 2002;16(6):579–86.

    Article  CAS  PubMed  Google Scholar 

  57. Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol. 2001;44(3):479–84.

    Article  CAS  PubMed  Google Scholar 

  58. Gupta AK, Del Rosso JQ. An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. Int J Dermatol. 2000;39(6):401–11.

    Article  CAS  PubMed  Google Scholar 

  59. Aventis Pharma. PENLAC® Nail Lacquer (ciclopirox) topical solution, 8% [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf. 31 Jan 2004.

  60. Curanail 5% Nail Lacquer (Amorolfine Hydrochloride) PL 10590/0049 [Internet]. MHRA. http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con2023787.pdf. Cited 8 Mar 2016.

  61. Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol. 2014;7(7):10–8.

    PubMed  PubMed Central  Google Scholar 

  62. Angelo T, Borgheti-Cardoso LN, Gelfuso GM, Taveira SF, Gratieri T. Chemical and physical strategies in onychomycosis topical treatment: a review. Med Mycol. 2017;55(5):461–75.

    CAS  PubMed  Google Scholar 

  63. Pollak RA, Jo Siu WJ, Tatsumi Y, Pillai R. Efinaconazole topical solution, 10%: factors contributing to onychomycosis success. J Fungi (Basel). 2015;1(2):107–14.

    Article  Google Scholar 

  64. Tabara K, Szewczyk AE, Bienias W, Wojciechowska A, Pastuszka M, Oszukowska M, et al. Amorolfine vs. ciclopirox – lacquers for the treatment of onychomycosis. Postepy Dermatol Alergol. 2015;32(1):40–5.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol. 2000;43(4 Suppl):S57–69.

    Article  CAS  PubMed  Google Scholar 

  66. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(4 Suppl):S70–80.

    Article  CAS  PubMed  Google Scholar 

  67. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol. 2000;42(2 Pt 1):217–24.

    Article  CAS  PubMed  Google Scholar 

  68. Gupta AK, Stec N. Recent advances in therapies for onychomycosis and its management. F1000Res. 2019;8

    Google Scholar 

  69. Seebacher C. Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis. Mycoses. 2003;46(11–12):506–10.

    Article  CAS  PubMed  Google Scholar 

  70. Lipner S, Scher RK. Onychomycosis: current and future therapies. Cutis. 2014;93(2):60–3.

    PubMed  Google Scholar 

  71. Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs. 1995;49(1):103–20.

    Article  CAS  PubMed  Google Scholar 

  72. Feng X, Xiong X, Ran Y. Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: a meta-analysis and systematic review. Dermatol Ther. 2017;30(3) https://doi.org/10.1111/dth.12457.

  73. Baran R, Feuilhade M, Combernale P, Datry A, Goettmann S, Pietrini P, et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol. 2000;142(6):1177–83.

    Article  CAS  PubMed  Google Scholar 

  74. Eichenfield LF, Friedlander SF. Pediatric onychomycosis: the emerging role of topical therapy. J Drugs Dermatol. 2016;16(2):105–9.

    Google Scholar 

  75. Sigurgeirsson B, Olafsson JH, Steinsson JT, Kerrouche N, Sidou F. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol. 2010;24(8):910–5.

    Article  CAS  PubMed  Google Scholar 

  76. Valeant Canada LP. PrJUBLIA™ Efinaconazole topical solution, 10% w/w. 2013.

    Google Scholar 

  77. Gupta AK, Simpson FC. Efinaconazole: a new topical treatment for onychomycosis. Skin Therapy Lett. 2014;19(1):1–4.

    PubMed  Google Scholar 

  78. Gupta AK, Mays RR, Versteeg SG, Shear NH, Friedlander SF. Onychomycosis in children: safety and efficacy of antifungal agents. Pediatr Dermatol. 2018;35(5):552–9.

    Article  PubMed  Google Scholar 

  79. Lipner SR, Scher RK. Efinaconazole in the treatment of onychomycosis. Infect Drug Resist. 2015;8:163–72.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Eichenfield LF, Elewski B, Sugarman J, Rosen T, Gupta A, Pillai R, et al. Safety, pharmacokinetics, and efficacy of Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients. J Drugs Dermatol. 2020;19(9):867–72.

    Article  PubMed  Google Scholar 

  81. Gupta AK, Studholme C. Update on Efinaconazole 10% topical solution for the treatment of onychomycosis. Skin Therapy Lett. 2016;21(6):7–11.

    CAS  PubMed  Google Scholar 

  82. Anacor Pharmaceuticals Inc. KERYDIN™ (tavaborole) topical solution, 5% [Internet]. US Food and Drug Administration; 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Cited 14 July 2014

  83. Generic Kerydin Availability – Drugs.com [Internet]. https://www.drugs.com/availability/generic-kerydin.html. Cited 18 Feb 2020.

  84. Abastabar M, Haghani I, Shokohi T, Hedayati MT, Aghili SR, Jedi A, et al. Low in vitro antifungal activity of Tavaborole against yeasts and moulds from onychomycosis. Antimicrob Agents Chemother. 2018;62(12):e1632–18.

    Article  Google Scholar 

  85. Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. Mycopathologia. 2017;182(1–2):127–41.

    Article  CAS  PubMed  Google Scholar 

  86. Gupta AK, Daigle D. Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults. Expert Rev Anti-Infect Ther. 2014;12(7):735–42.

    Article  CAS  PubMed  Google Scholar 

  87. Aly R, Gupta AK, Winter T, Zane LT, Vlahovic T. Tavaborole in difficult-to-treat onychomycosis cases: a post-hoc assessment of phase III subjects. J Drugs Dermatol. 2017;16(10):1016–21.

    CAS  PubMed  Google Scholar 

  88. Rich P, Spellman M, Purohit V, Zang C, Crook TJ. Tavaborole 5% topical solution for the treatment of toenail onychomycosis in pediatric patients: results from a phase 4 open-label study. J Drugs Dermatol. 2019;18(2):190–5.

    CAS  PubMed  Google Scholar 

  89. Gayam V, Khalid M, Dahal S, Garlapati P, Gill A. Hyperacute liver injury following intravenous fluconazole: a rare case of dose-independent hepatotoxicity. J Family Med Prim Care. 2018;7(2):451.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Lawson C-A, Karlowsky JA. Fluconazole-induced hepatotoxicity: review of published case reports. Can J Hosp Pharm. 1998;51(2):3.

    Google Scholar 

  91. US Food and Drug Administration. Medical devices and clinical trial design for the treatment or improvement in the appearance of fungally-infected nails – draft guidance for industry and FDA staff [Internet]. 2015. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM431312.pdf. Cited 22 May 2015.

  92. Gupta AK, Foley KA, Versteeg SG. Lasers for onychomycosis. J Cutan Med Surg. 2017;21(2):114–6.

    Article  PubMed  Google Scholar 

  93. Hay R. Therapy of skin, hair and nail fungal infections. J Fungi (Basel). 2018;4(3):99.

    Article  CAS  Google Scholar 

  94. Gupta AK, Simpson FC, Heller DF. The future of lasers in onychomycosis. J Dermatolog Treat. 2016;27(2):167–72.

    Article  CAS  PubMed  Google Scholar 

  95. Gupta AK, Simpson F. Newly approved laser systems for onychomycosis. J Am Podiatr Med Assoc. 2012;102(5):428–30.

    Article  PubMed  Google Scholar 

  96. Vlahovic TC. Onychomycosis: evaluation, treatment options, managing recurrence, and patient outcomes. Clin Podiatr Med Surg. 2016;33(3):305–18.

    Article  PubMed  Google Scholar 

  97. Gupta AK, Simpson FC. New pharmacotherapy for the treatment of onychomycosis: an update. Expert Opin Pharmacother. 2015;16(2):227–36.

    Article  CAS  PubMed  Google Scholar 

  98. Nenoff P, Grunewald S, Paasch U. Laser therapy of onychomycosis. J Dtsch Dermatol Ges. 2014;12(1):33–8.

    PubMed  Google Scholar 

  99. Nair AB, Vaka SRK, Murthy SN. Transungual delivery of terbinafine by iontophoresis in onychomycotic nails. Drug Dev Ind Pharm. 2011;37(10):1253–8.

    Article  CAS  PubMed  Google Scholar 

  100. Nematollahi AR, Badiee P, Nournia E. The efficacy of ultraviolet irradiation on Trichophyton species isolated from nails. Jundishapur J Microbiol. 2015;8(6):e18158.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Carney C, Cantrell W, Warner J, Elewski B. Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser. J Am Acad Dermatol. 2013;69(4):578–82.

    Article  PubMed  Google Scholar 

  102. Karsai S, Jäger M, Oesterhelt A, Weiss C, Schneider SW, Jünger M, et al. Treating onychomycosis with the short-pulsed 1064-nm-Nd:YAG laser: results of a prospective randomized controlled trial. J Eur Acad Dermatol Venereol. 2017;31(1):175–80.

    Article  CAS  PubMed  Google Scholar 

  103. Hees H, Jäger MW, Raulin C. Treatment of onychomycosis using the 1 064 nm Nd:YAG laser: a clinical pilot study. J Dtsch Dermatol Ges. 2014;12(4):322–9.

    PubMed  Google Scholar 

  104. Noguchi H, Miyata K, Sugita T, Hiruma M, Hiruma M. Treatment of onychomycosis using a 1064 nm Nd:YAG laser. Med Mycol J. 2013;54(4):333–9.

    Article  PubMed  Google Scholar 

  105. Kimura U, Takeuchi K, Kinoshita A, Takamori K, Hiruma M, Suga Y. Treating onychomycoses of the toenail: clinical efficacy of the sub-millisecond 1,064 nm Nd: YAG laser using a 5 mm spot diameter. J Drugs Dermatol. 2012;11(4):496–504.

    CAS  PubMed  Google Scholar 

  106. Renner R, Grüsser K, Sticherling M. 1,064-nm diode laser therapy of onychomycosis: results of a prospective open treatment of 82 toenails. Dermatology (Basel). 2015;230(2):128–34.

    Article  CAS  Google Scholar 

  107. Lim E-H, Kim H, Park Y-O, Lee Y, Seo Y-J, Kim C-D, et al. Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream. J Am Acad Dermatol. 2014;70(5):918–23.

    Article  PubMed  Google Scholar 

  108. Shi J, Li J, Huang H, Permatasari F, Liu J, Xu Y, et al. The efficacy of fractional carbon dioxide (CO2) laser combined with terbinafine hydrochloride 1% cream for the treatment of onychomycosis. J Cosmet Laser Ther. 2017;19(6):353–9.

    Article  PubMed  Google Scholar 

  109. de Oliveira GB, Antonio JR, Antonio CR, Tomé FA. The association of fractional CO2 laser 10.600nm and photodynamic therapy in the treatment of onychomycosis. An Bras Dermatol. 2015;90(4):468–71.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Xu Y, Miao X, Zhou B, Luo D. Combined oral terbinafine and long-pulsed 1,064-nm Nd: YAG Laser treatment is more effective for onychomycosis than either treatment alone. Dermatol Surg. 2014;40(11):1201–7.

    Article  CAS  PubMed  Google Scholar 

  111. Watanabe D, Kawamura C, Masuda Y, Akita Y, Tamada Y, Matsumoto Y. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol. 2008;144(1):19–21.

    Article  PubMed  Google Scholar 

  112. Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol. 2008;59(5 Suppl):S75–6.

    Article  PubMed  Google Scholar 

  113. Gilaberte Y, Aspiroz C, Martes MP, Alcalde V, Espinel-Ingroff A, Rezusta A. Treatment of refractory fingernail onychomycosis caused by nondermatophyte molds with methylaminolevulinate photodynamic therapy. J Am Acad Dermatol. 2011;65(3):669–71.

    Article  PubMed  Google Scholar 

  114. Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, Apalla Z, Ioannides D. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: preliminary results of a single-centre open trial. Acta Derm Venereol. 2010;90(2):216–7.

    Article  PubMed  Google Scholar 

  115. Souza LWF, Souza SVT, Botelho AC d C. Distal and lateral toenail onychomycosis caused by Trichophyton rubrum: treatment with photodynamic therapy based on methylene blue dye. An Bras Dermatol. 2014;89(1):184–6.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Aspiroz C, Fortuño-Cebamanos B, Rezusta A, Gilaberte Y. Photodynamic therapy with methyl-aminolevulinate can be useful in the management of Scytalidium infections. Actas Dermosifiliogr. 2013;104(8):725–7.

    Article  CAS  PubMed  Google Scholar 

  117. Nair AB, Kim HD, Chakraborty B, Singh J, Zaman M, Gupta A, et al. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci. 2009;98(11):4130–40.

    Article  CAS  PubMed  Google Scholar 

  118. Nair AB, Kim HD, Davis SP, Etheredge R, Barsness M, Friden PM, et al. An ex vivo toe model used to assess applicators for the iontophoretic ungual delivery of terbinafine. Pharm Res. 2009;26(9):2194–201.

    Article  CAS  PubMed  Google Scholar 

  119. Shemer A, Gupta AK, Amichai B, Farhi R, Baran R, Daniel CR, et al. An open comparative study of nail drilling as adjunctive treatment for toenail onychomycosis. J Dermatolog Treat. 2016;27(5):480–3.

    Article  CAS  PubMed  Google Scholar 

  120. Vanstone S, Cordery SF, Stone JM, Gordeev SN, Guy RH. Precise laser poration to control drug delivery into and through human nail. J Control Release. 2017;268:72–7.

    Article  CAS  PubMed  Google Scholar 

  121. Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R, Taskforce on Onychomycosis Education. Treatment options—development of consensus guidelines. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):25–33.

    Article  PubMed  Google Scholar 

  122. Lahfa M, Bulai-Livideanu C, Baran R, Ortonne JP, Richert B, Tosti A, et al. Efficacy, safety and tolerability of an optimized avulsion technique with Onyster® (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized evaluator-blinded controlled study. Dermatology (Basel). 2013;226(1):5–12.

    Article  CAS  Google Scholar 

  123. Gupta AK, Lynch LE. Management of onychomycosis: examining the role of monotherapy and dual, triple, or quadruple therapies. Cutis. 2004;74(1 Suppl):5–9.

    PubMed  Google Scholar 

  124. Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol. 2013;31(5):544–54.

    Article  PubMed  Google Scholar 

  125. Repka MA, Majumdar S, Kumar Battu S, Srirangam R, Upadhye SB. Applications of hot-melt extrusion for drug delivery. Expert Opin Drug Deliv. 2008;5(12):1357–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Thiry J, Lebrun P, Vinassa C, Adam M, Netchacovitch L, Ziemons E, et al. Continuous production of itraconazole-based solid dispersions by hot melt extrusion: preformulation, optimization and design space determination. Int J Pharm. 2016;515(1–2):114–24.

    Article  CAS  PubMed  Google Scholar 

  127. Maddin S, Quiring J, Bulger L. Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis. J Drugs Dermatol. 2013;12(7):758–63.

    PubMed  Google Scholar 

  128. Elewski B, Kempers S, Bhatia N, Blauvelt A, Curelop S, Brand S, et al. Efficacy and safety of VT-1161 in a randomized, double-blind, placebo-controlled study of four oral VT-1161 regimens in the treatment of patients with moderate-to-severe Distal-Lateral Subungual Onychomycosis (DLSO). In: Fourth international summit for nail diseases, 2017, Athens, Greece.

    Google Scholar 

  129. Gupta AK, Stec N. Emerging drugs for the treatment of onychomycosis. Expert Opin Emerg Drugs. 2019;24(4):213–20.

    Article  CAS  PubMed  Google Scholar 

  130. Gupta AK, Leonadri C, Pierce P, Conetta B. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol. 2005;19(4):437–43.

    Article  CAS  PubMed  Google Scholar 

  131. Oral Antifungal Agent Nailin® Capsules 100mg Approved In JAPAN | News Release:2018 | Eisai Co., Ltd. [Internet]. https://www.eisai.com/news/2018/news201806.html. Cited 28 Jan 2020.

  132. Watanabe S, Tsubouchi I, Okubo A. Efficacy and safety of fosravuconazole l-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: a multicenter, double-blind, randomized phase III study. J Dermatol. 2018;45(10):1151–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012;166(2):389–98.

    Article  CAS  PubMed  Google Scholar 

  134. Sigurgeirsson B, van Rossem K, Malahias S, Raterink K. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol. 2013;69(3):416–25.

    Article  CAS  PubMed  Google Scholar 

  135. Baran R, Tosti A, Hartmane I, Altmeyer P, Hercogova J, Koudelkova V, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol. 2009;23(7):773–81.

    Article  CAS  PubMed  Google Scholar 

  136. Monti D, Saccomani L, Chetoni P, Burgalassi S, Saettone MF, Mailland F. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev Ind Pharm. 2005;31(1):11–7.

    Article  CAS  PubMed  Google Scholar 

  137. Study to evaluate the efficacy and safety of P-3058 nail solution in the treatment of onychomycosis – full text view – ClinicalTrials.gov [Internet]. https://clinicaltrials.gov/ct2/show/NCT03094468. Cited 28 Jan 2020.

  138. Kreutz T, de Matos SP, Koester LS. Recent patents containing permeation enhancers for nail delivery. Recent Pat Drug Deliv Formul. 2019;13(3):203–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Takahata S, Kubota N, Takei-Masuda N, Yamada T, Maeda M, Alshahni MM, et al. Mechanism of action of ME1111, a novel antifungal agent for topical treatment of onychomycosis. Antimicrob Agents Chemother. 2016;60(2):873–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Moberg Pharma AB. Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosis [Internet]. News Powered by Cision. 2019. https://news.cision.com/moberg-pharma/r/moberg-pharma-meets-primary-endpoint-for-mob-015-in-a-phase-3-study-for-the-treatment-of-onychomycos,c2984987. Cited 7 Jan 2020.

  141. Gupta AK, Surprenant MS, Kempers SE, Pariser DM, Rensfeldt K, Tavakkol A. Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study. J Am Acad Dermatol. 2020 Jun 22:S0190-9622(20)31153–1. https://doi.org/10.1016/j.jaad.2020.06.055. Epub ahead of print.

  142. Ghannoum M, Isham N, Herbert J, Henry W, Yurdakul S. Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations. J Clin Microbiol. 2011;49(5):1716–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Costa-Orlandi CB, Mordorski B, Baltazar LM, Mendes-Giannini MJS, Friedman JM, Nosanchuk JD, et al. Nitric oxide releasing nanoparticles as a strategy to improve current onychomycosis treatments. J Drugs Dermatol. 2018;17(7):717–20.

    CAS  PubMed  Google Scholar 

  144. Finnen MJ, Hennessy A, McLean S, Bisset Y, Mitchell R, Megson IL, et al. Topical application of acidified nitrite to the nail renders it antifungal and causes nitrosation of cysteine groups in the nail plate. Br J Dermatol. 2007;157(3):494–500.

    Article  CAS  PubMed  Google Scholar 

  145. Weller R, Ormerod AD, Hobson RP, Benjamin NJ. A randomized trial of acidified nitrite cream in the treatment of tinea pedis. J Am Acad Dermatol. 1998;38(4):559–63.

    Article  CAS  PubMed  Google Scholar 

  146. Zhao Y, Lim J, Xu J, Yu J-H, Zheng W. Nitric oxide as a developmental and metabolic signal in filamentous fungi. Mol Microbiol. 2020;113(5):872–82.

    Article  CAS  PubMed  Google Scholar 

  147. Lipner SR, Friedman G, Scher RK. Pilot study to evaluate a plasma device for the treatment of onychomycosis. Clin Exp Dermatol. 2017;42(3):295–8.

    Article  CAS  PubMed  Google Scholar 

  148. Flores FC, Chiu WS, Beck RCR, da Silva CB, Delgado-Charro MB. Enhancement of tioconazole ungual delivery: combining nanocapsule formulation and nail poration approaches. Int J Pharm. 2018;535(1–2):237–44.

    Article  CAS  PubMed  Google Scholar 

  149. Gupta AK, Versteeg SG, Shear NH, Piguet V, Tosti A, Piraccini BM. A practical guide to curing nychomycosis: how to maximize cure at the patient, organism, treatment, and environmental level. Am J Clin Dermatol. 2019;20(1):123–33.

    Article  PubMed  Google Scholar 

  150. How common is relapse or reinfection in onychomycosis? [Internet]. https://www.medscape.com/answers/1105828-22690/how-common-is-relapse-or-reinfection-in-onychomycosis. Cited 28 Jan 2020.

  151. Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol. 2003;149(Suppl 65):5–9.

    Article  PubMed  Google Scholar 

  152. Gupta AK, Elewski BE, Rosen T, Caldwell B, Pariser DM, Kircik LH, et al. Onychomycosis: strategies to minimize recurrence. J Drugs Dermatol. 2016;15(3):279–82.

    CAS  PubMed  Google Scholar 

  153. Tosti A, Elewski BE. Onychomycosis: practical approaches to minimize relapse and recurrence. Skin Appendage Disord. 2016;2(1–2):83–7.

    Article  PubMed  PubMed Central  Google Scholar 

  154. Lipner SR, Scher RK. Onychomycosis: treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80(4):853–67.

    Article  PubMed  Google Scholar 

  155. Gupta AK, Studholme C. Novel investigational therapies for onychomycosis: an update. Expert Opin Investig Drugs. 2016;25(3):297–305.

    Article  CAS  PubMed  Google Scholar 

  156. Yin Z, Xu J, Luo D. A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole. J Dermatolog Treat. 2012;23(6):449–52.

    Article  CAS  PubMed  Google Scholar 

  157. Gupta AK, Cooper EA, Paquet M. Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono- and combined therapy of terbinafine and itraconazole. J Cutan Med Surg. 2013;17(3):201–6.

    Article  CAS  PubMed  Google Scholar 

  158. Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology (Basel). 1998;197(2):162–6.

    Article  CAS  Google Scholar 

  159. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EGV. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138(3):353–7.

    Article  CAS  PubMed  Google Scholar 

  160. Rosen T, Gold LS. Antifungal drugs for onychomycosis: efficacy, safety, and mechanisms of action. Semin Cutan Med Surg. 2016;35(3, Suppl 3):51–5.

    Article  Google Scholar 

  161. Gupta AK, Baran R. Ciclopirox nail lacquer solution 8% in the 21st century. J Am Acad Dermatol. 2000;43(4 Suppl):S96–102.

    Article  CAS  PubMed  Google Scholar 

  162. Monod M, Méhul B. Recent findings in onychomycosis and their application for appropriate treatment. J Fungi (Basel). 2019;5(1):20.

    Article  CAS  Google Scholar 

  163. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125(1 Suppl):S3–13.

    Article  CAS  PubMed  Google Scholar 

  164. Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal biofilms and drug resistance. Emerg Infect Dis. 2004;10(1):14–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Gianni C, Cerri A, Crosti C. Non-dermatophytic onychomycosis. An underestimated entity? A study of 51 cases. Mycoses. 2000;43(1–2):29–33.

    Article  CAS  PubMed  Google Scholar 

  166. Pierce CG, Thomas DP, López-Ribot JL. Effect of tunicamycin on Candida albicans biofilm formation and maintenance. J Antimicrob Chemother. 2009;63(3):473–9.

    Article  CAS  PubMed  Google Scholar 

  167. Gupta AK, Daigle D, Carviel JL. The role of biofilms in onychomycosis. J Am Acad Dermatol. 2016;74(6):1241–6.

    Article  CAS  PubMed  Google Scholar 

  168. Nusbaum AG, Kirsner RS, Charles CA. Biofilms in dermatology. Skin Therapy Lett. 2012;17(7):1–5.

    CAS  PubMed  Google Scholar 

  169. Vila TVM, Rozental S, de Sá Guimarães CMD. A new model of in vitro fungal biofilms formed on human nail fragments allows reliable testing of laser and light therapies against onychomycosis. Lasers Med Sci. 2015;30(3):1031–9.

    Article  PubMed  Google Scholar 

  170. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, Pitula A. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun. 2004;72(10):6023–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Song JW, Shin JH, Kee SJ, Kim SH, Shin MG, Suh SP, et al. Expression of CgCDR1, CgCDR2, and CgERG11 in Candida glabrata biofilms formed by bloodstream isolates. Med Mycol. 2009;47(5):545–8.

    Article  CAS  PubMed  Google Scholar 

  172. Gupta AK, Taborda VBA, Taborda PRO, Shemer A, Nakrieko K-A. High prevalence of mixed infections in global onychomycosis. In: 2020 American Academy of Dermatology annual meeting, March 20, Denver, Colorado.

    Google Scholar 

  173. Ogasawara Y, Hiruma M, Muto M, Ogawa H. Clinical and mycological study of occult tinea pedis and tinea unguium in dermatological patients from Tokyo. Mycoses. 2003;46(3–4):114–9.

    Article  CAS  PubMed  Google Scholar 

  174. Tosti A, Hay R, Arenas-Guzmán R. Patients at risk of onychomycosis—risk factor identification and active prevention. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):13–6.

    Article  PubMed  Google Scholar 

  175. Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat. 2005;16(5–6):327–30.

    Article  CAS  PubMed  Google Scholar 

  176. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol. 2001;145(Suppl 60):21–6.

    Article  CAS  PubMed  Google Scholar 

  177. Cohen PR, Scher RK. Topical and surgical treatment of onychomycosis. J Am Acad Dermatol. 1994;31(3, Part 2):S74–7.

    Article  CAS  PubMed  Google Scholar 

  178. Gupta AK, Mays RR, Versteeg SG, Piraccini BM, Takwale A, Shemer A, et al. Global perspectives for the management of onychomycosis. Int J Dermatol. 2019;58(10):1118–29.

    Article  PubMed  Google Scholar 

  179. Sakamoto M, Sugimoto N, Kawabata H, Yamakawa E, Kodera N, Pillai R, et al. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails. J Drugs Dermatol. 2014;13(11):1388–92.

    CAS  PubMed  Google Scholar 

  180. Hold KM, Sanders V, Bu W, Baker SJ, Plattner JJ, Maples KR, et al. Nail penetration and nail concentration of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis [Internet]. Palo Alto, CA: Anacor Pharmaceuticals Inc.. http://www.anacor.com/news/posters/aaps_2006_final.pdf.

Download references

Author information

Authors and Affiliations

  1. Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Aditya K. Gupta

  2. Mediprobe Research Inc., London, ON, Canada

    Aditya K. Gupta, Maanasa Venkataraman & Emma M. Quinlan

Authors
  1. Aditya K. Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maanasa Venkataraman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emma M. Quinlan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aditya K. Gupta .

Editor information

Editors and Affiliations

  1. Univ Angers, Université de Bretagne Occidentale, CHU, SFR ICAT, Groupe d’Etude des Interactions Hôte-Pathogène (GEIHP, EA 3142), Angers, France

    Jean-Philippe Bouchara

  2. Laboratory for Medical Microbiology, Rötha, Sachsen, Germany

    Pietro Nenoff

  3. Mediprobe Research Inc., London, ON, Canada

    Aditya K. Gupta

  4. New York State Department of Health Wadsworth Center, Mycology Laboratory, Albany, NY, USA

    Vishnu Chaturvedi

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gupta, A.K., Venkataraman, M., Quinlan, E.M. (2021). New Antifungal Agents and New Formulations Against Dermatophytes. In: Bouchara, JP., Nenoff, P., Gupta, A.K., Chaturvedi, V. (eds) Dermatophytes and Dermatophytoses. Springer, Cham. https://doi.org/10.1007/978-3-030-67421-2_21

Download citation

Publish with us

Policies and ethics

Search

Navigation